Wu Zhulin, Yang Lina, He Li, Wang Lianan, Peng Lisheng
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
Evid Based Complement Alternat Med. 2020 Apr 24;2020:4763675. doi: 10.1155/2020/4763675. eCollection 2020.
In this study, the data mining method was used to screen the core Chinese materia medicas (CCMMs) against primary liver cancer (PLC), and the potential mechanisms of CCMMs in treating PLC were analyzed based on network pharmacology.
Traditional Chinese medicine (TCM) prescriptions for treating PLC were obtained from a famous TCM doctor in Shenzhen, China. According to the data mining technique, the TCM Inheritance Support System (TCMISS) was applied to excavate the CCMMs in the prescriptions. Then, bioactive ingredients and corresponding targets of CCMMs were collected using three different TCM online databases, and target genes of PLC were obtained from GeneCards and OMIM. Afterwards, common targets of CCMMs and PLC were screened. Furthermore, a network of CCMMs bioactive ingredients and common target gene was constructed by Cytoscape 3.7.1, and gene ontology (GO) and signaling pathways analyses were performed to explain the mechanism of CCMMs in treating PLC. Besides, protein-protein interaction (PPI) analysis was used to identify key target genes of CCMMs, and the prognostic value of key target genes was verified using survival analysis.
A total of 15 high-frequency Chinese materia medica combinations were found, and CCMMs (including Paeoniae Radix Alba, Radix Bupleuri, Macrocephalae Rhizoma, Coicis Semen, Poria, and Curcumae Radix) were identified by TCMISS. A total of 40 bioactive ingredients (e.g., quercetin, kaempferol, and naringenin) of CCMMs were obtained, and 202 common target genes of CCMMs and PLC were screened. GO analysis indicated that biological processes of CCMMs were mainly involved in response to drug, response to ethanol, etc. Pathway analysis demonstrated that CCMMs exerted its antitumor effects by acting on multiple signaling pathways, including PI3K-Akt, TNF, and MAPK pathways. Also, some key target genes of CCMMs were determined by PPI analysis, and four genes (MAPK3, VEGFA, EGF, and EGFR) were found to be correlated with survival in PLC patients.
Based on data mining and network pharmacology methods, our results showed that the therapeutic effect of CCMMs on PLC may be realized by acting on multitargets and multipathways related to the occurrence and development of PLC.
本研究运用数据挖掘方法筛选治疗原发性肝癌(PLC)的核心中药,并基于网络药理学分析其治疗PLC的潜在机制。
从中国深圳一位著名中医处获取治疗PLC的中药方剂。依据数据挖掘技术,应用中医传承辅助系统(TCMISS)挖掘方剂中的核心中药。然后,利用三个不同的中药在线数据库收集核心中药的生物活性成分及相应靶点,并从GeneCards和OMIM获取PLC的靶基因。之后,筛选核心中药与PLC的共同靶点。此外,通过Cytoscape 3.7.1构建核心中药生物活性成分与共同靶基因的网络,并进行基因本体(GO)和信号通路分析以阐释核心中药治疗PLC的机制。此外,采用蛋白质-蛋白质相互作用(PPI)分析鉴定核心中药的关键靶基因,并通过生存分析验证关键靶基因的预后价值。
共发现15个高频中药组合,通过TCMISS鉴定出核心中药(包括白芍、柴胡、白术、薏苡仁、茯苓和郁金)。共获得核心中药的40种生物活性成分(如槲皮素、山奈酚和柚皮素),筛选出核心中药与PLC的202个共同靶基因。GO分析表明,核心中药的生物学过程主要涉及对药物的反应、对乙醇的反应等。通路分析显示,核心中药通过作用于多个信号通路发挥抗肿瘤作用,包括PI3K-Akt、TNF和MAPK通路。此外,通过PPI分析确定了核心中药的一些关键靶基因,发现四个基因(MAPK3、VEGFA、EGF和EGFR)与PLC患者的生存相关。
基于数据挖掘和网络药理学方法,我们的结果表明,核心中药对PLC的治疗作用可能是通过作用于与PLC发生发展相关的多靶点和多途径实现的。